Search
Semaglutide Treatment Options
A collection of 189 research studies where Semaglutide is the interventional treatment. These studies are located in the United States. Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
1 - 12 of 189
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Dilated Cardiomyopathy (DCM) Research Study
Recruiting
If you are identified as eligible for investigational genetic testing, you will be sent a saliva collection kit to your home. Once you have completed and returned your kit to Sano Genetics, your sample will be tested for a specific genetic pathway called BAG3.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Conditions:
Dilated Cardiomyopathy (DCM)
Cardiovascular Diseases
Cardiomyopathy
Cardiovascular Disease
Heart Failure
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Recruiting
The recent introduction of the new generation of anti-obesity medications (AOMs) will change the future of obesity treatment. These highly effective medications, such as high-dose semaglutide and tirzepatide, are hormone analogues that augment the incretin function and exert multiple physiological effects by activating glucagon-like peptide-1 (GLP-1) and/or glucose-dependent insulinotropic polypeptide (GIP) distributed in various organs. These medications provide an average of 15-22% weight redu... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: The Cleveland Clinic, Cleveland, Ohio
Conditions: Obesity and Obesity-related Medical Conditions
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
Completed
This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients with T2D with adequate glycemic control (≤ 7.5%) on MDI-based regimens (≤ 80 units of insulin per day), vs. further titration of insulin therapy in those continuing MDI. Weight loss, hypoglycemic episodes, and improvement in di... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/03/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Type 2 Diabetes
Effects of Semaglutide in HIV-Associated Lipohypertrophy
Active Not Recruiting
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream effect of cardiovascular risk in people with HIV. The primary endpoints will be visceral and ectopic fat changes over the study period. The secondary endpoints will include changes in markers of inflammation, immune activation, gut integrity, and cardiovascular disease ris... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Case Western Reserve University, Cleveland, Ohio +1 locations
Conditions: HIV/AIDS, Lipohypertrophy, Obesity
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Active Not Recruiting
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSem... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/29/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +224 locations
Conditions: Obesity
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Recruiting
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Valley Clinical Trials, Covina, California +36 locations
Conditions: Obesity
Semaglutide in CFRD
Completed
This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Pharmacogenetics of Response to GLP1R Agonists
Recruiting
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims:
1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated fir... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
06/26/2025
Locations: Amish Research Clinic, Lancaster, Pennsylvania
Conditions: Obesity, Diabetes Type 2
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Active Not Recruiting
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/24/2025
Locations: Banner Alzheimer's Institute, Phoenix, Arizona +342 locations
Conditions: Early Alzheimer's Disease
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
Active Not Recruiting
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/24/2025
Locations: Banner Alzheimer's Institute, Phoenix, Arizona +389 locations
Conditions: Early Alzheimer´s Disease
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
Not Yet Recruiting
This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/18/2025
Locations: Atlanta VA Medical Center, Decatur, Georgia
Conditions: Alcohol Use Disorder (AUD), HIV
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Active Not Recruiting
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Del Sol Research Management, LLC, Tucson, Arizona +180 locations
Conditions: Diabetes Mellitus, Type 2
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
Completed
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/17/2025
Locations: North AL Health Res, LLC, Huntsville, Alabama +183 locations
Conditions: Non-alcoholic Steatohepatitis
1 - 12 of 189